Eli Lilly Reports Results of Emgality (galcanezumab-gnlm) in Three P-III Studies for Chronic and Episodic Migraine

 Eli Lilly Reports Results of Emgality (galcanezumab-gnlm) in Three P-III Studies for Chronic and Episodic Migraine

Eli Lilly Reports Results of Emgality (galcanezumab-gnlm) in Three P-III Studies for Chronic and Episodic Migraine

Shots:

  • The P-III studies include REGAIN and EVOLVE-1 & 2 assessing Emgality vs PBO in patients with chronic and episodic migraine respectively
  • Post-hoc analyses results: reductions in disability in chronic migraine (20.3% vs 13.9%); @6mos. little/no disability in episodic migraine (44.0% vs 26.5%); improvement in daily functioning
  • Emgality is a mAb targeting CGRP and has received EMA’s approval for the prophylaxis of migraine in Nov’2018 and FDA’s approval for migraine and episodic cluster headache in adults in Sept’2018 and Jun’2019 respectively

Click here to read full press release/ article | Ref: Lilly | Image: Behance

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post